Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Advertise with Us Top Online Brokers Become an Affiliate TipRanks News Wire Arrived EquityMultiple

TOOLS

Technical Analysis Screener

Top Analyst Stocks

Popular

Top Smart Score Stocks

Daily Analyst Ratings

Daily Insiders Trades

Dividend Stocks

ETF Center

Top Gainers/losers/active ETFs

Dividend Calculator

Options Profit Calculator

Dollar Cost Averaging

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Real Estate

Top Online Brokers

Compound Interest Calculator

Mortgage Calculator

Auto Loan Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

STOCKS

Kyverna Therapeutics, Inc. (KYTX)

NASDAQ:KYTX

KYTX

Kyverna Therapeutics, Inc.

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Kyverna Therapeutics, Inc. (KYTX) Stock Forecast & Price Target

Compare

646 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KYTX Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Kyverna

Therapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KYTX Stock 12 Month Forecast

Average Price Target

$40.00

▲(1500.00% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Kyverna Therapeutics, Inc. in the last 3 months. The average price target is $40.00 with a high forecast of $40.00 and a low forecast of $40.00. The average price target represents a 1500.00% change from the last price of $2.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","41":"$41","11.75":"$11.75","21.5":"$21.5","31.25":"$31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,11.75,21.5,31.25,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.74,6.52923076923077,9.318461538461538,12.107692307692307,14.896923076923077,17.686153846153847,20.475384615384613,23.264615384615382,26.053846153846152,28.84307692307692,31.63230769230769,34.42153846153846,37.21076923076923,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.74,6.52923076923077,9.318461538461538,12.107692307692307,14.896923076923077,17.686153846153847,20.475384615384613,23.264615384615382,26.053846153846152,28.84307692307692,31.63230769230769,34.42153846153846,37.21076923076923,{"y":40,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.74,6.52923076923077,9.318461538461538,12.107692307692307,14.896923076923077,17.686153846153847,20.475384615384613,23.264615384615382,26.053846153846152,28.84307692307692,31.63230769230769,34.42153846153846,37.21076923076923,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.1,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.75,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.75,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.52,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.61,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.53,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.81,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.73,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$40.00

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Reiterated

01/13/25

Reiterated

01/13/25

xxxxxxxxxxxxx

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

12/03/24

Analysts Are Bullish on Top NA Stocks: Rubrik, Inc. Class A (RBRK), Kyverna Therapeutics, Inc. (KYTX)

Mitchell Kapoor

H.C. Wainwright

$7→$6

Hold

140.00%

Upside

Reiterated

11/20/24

Analysts Offer Insights on NA Companies: Viking Holdings Ltd (NYSE: VIK), Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and Amer Sports, Inc. (NYSE: AS)

Derek Archila

Wells Fargo

$44→$24

Buy

860.00%

Upside

Assigned

11/14/24

Kyverna Therapeutics price target lowered to $24 from $44 at Wells FargoKyverna Therapeutics price target lowered to $24 from $44 at Wells Fargo

Trung Huynh

UBS

$13

Buy

420.00%

Upside

Initiated

10/10/24

Kyverna Therapeutics initiated with a Buy at UBSKyverna Therapeutics initiated with a Buy at UBS

Anthony Butler

Rodman & Renshaw

$16

Buy

540.00%

Upside

Initiated

10/09/24

Kyverna Therapeutics initiated with a Buy at Rodman & RenshawKyverna Therapeutics initiated with a Buy at Rodman & Renshaw

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Reiterated

01/13/25

Reiterated

01/13/25

xxxxxxxxxxxxx

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

12/03/24

Analysts Are Bullish on Top NA Stocks: Rubrik, Inc. Class A (RBRK), Kyverna Therapeutics, Inc. (KYTX)

Mitchell Kapoor

H.C. Wainwright

$7→$6

Hold

140.00%

Upside

Reiterated

11/20/24

Analysts Offer Insights on NA Companies: Viking Holdings Ltd (NYSE: VIK), Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and Amer Sports, Inc. (NYSE: AS)

Derek Archila

Wells Fargo

$44→$24

Buy

860.00%

Upside

Assigned

11/14/24

Kyverna Therapeutics price target lowered to $24 from $44 at Wells FargoKyverna Therapeutics price target lowered to $24 from $44 at Wells Fargo

Trung Huynh

UBS

$13

Buy

420.00%

Upside

Initiated

10/10/24

Kyverna Therapeutics initiated with a Buy at UBSKyverna Therapeutics initiated with a Buy at UBS

Anthony Butler

Rodman & Renshaw

$16

Buy

540.00%

Upside

Initiated

10/09/24

Kyverna Therapeutics initiated with a Buy at Rodman & RenshawKyverna Therapeutics initiated with a Buy at Rodman & Renshaw

Stocks with the Highest Top Analyst Consensus in the General Sector

xxx

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

KYTX Analyst Recommendation Trends

Rating

Sep 24

Oct 24

Nov 24

Dec 24

Jan 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KYTX has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KYTX average Analyst price target in the past 3 months is $40.00.

Each month's total comprises the sum of three months' worth of ratings.

KYTX Financial Forecast

KYTX Earnings Forecast

Next quarter’s earnings estimate for KYTX is -$1.04 with a range of -$1.08 to -$1.01. The previous quarter’s EPS was -$0.74. KYTX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.14% of the time in the same period. In the last calendar year KYTX has Outperformed its overall industry.

No data currently available

KYTX Sales Forecast

Next quarter’s sales forecast for KYTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KYTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 75.00% of the time in the same period. In the last calendar year KYTX has Preformed in-line its overall industry.

KYTX Stock Forecast FAQ

What is KYTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Kyverna Therapeutics, Inc.’s 12-month average price target is $40.00.

What is KYTX’s upside potential, based on the analysts’ average price target?

Kyverna Therapeutics, Inc. has 1500.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KYTX a Buy, Sell or Hold?

Kyverna Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is Kyverna Therapeutics, Inc.’s price target?

The average price target for Kyverna Therapeutics, Inc. is $40.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $40.00. The average price target represents 1500.00% Increase from the current price of $2.5.

What do analysts say about Kyverna Therapeutics, Inc.?

Kyverna Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of KYTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Kyverna Therapeutics, Inc. (KYTX) Stock Forecast & Price Target

KYTX Analyst Ratings

KYTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

KYTX Analyst Recommendation Trends

KYTX Financial Forecast

KYTX Earnings Forecast

KYTX Sales Forecast

KYTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts